drugset / Trial / NCT06700148

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds

NCT06700148

Phase 3 Active not recruiting 840 enrolled CanSino Biologics Inc.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a randomized, blinded, peer-controlled study. There will be 2 treatment groups, screened subjects were given study numbers in the order of enrollment and randomly assigned to the test and control groups in a 1:1 ratio. Subjects were required to complete a 1-dose immunization program with 0.5 ml of vaccine in both the test and control groups, afterwards some subjects entered the immune persistence group.

Timeline

Start
2024-12-14
Primary completion
2025-08-30
Completion
2025-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject MCV4 Vaccine 0.5 ml
Comparator MPSV4 Vaccine 0.5 ml